We quantified this phenomenon, showing that a significant proportion of previously untreated MM patients (at least one out of five) completely fails CD34+ PBSC collection or does not reach an adequate number after a standard mobilizing procedure. This evidence concerns the gene CD34 and Miyoshi myopathy.